Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Chris Christie says it’s “undeniable” he got COVID from Trump

In a “Firing Line” interview, Christie said that it’s “inexcusable” Meadows didn’t tell them about Trump’s positive COVID test and instead saved it for his book.

“I would have worn a mask if I knew that,” Christie said. “We knew everybody in that room, except for the president, was getting tested every day. We didn’t know what the president’s testing regimen was.”

“So if Mark Meadows knew that somebody that I was sitting across from for four days had popped the positive test, [he] should have told us,” he added.

“He didn’t tell us,” Christie said. “I went into the hospital in the intensive care unit. He didn’t call and tell me. So I think that’s inexcusable.”

Source: Axios

https://www.axios.com/chris-christie-mark-meadows-donald-trump-covid-19-d9cf21cc-0bb3-459c-b04c-3aabfcfb5c20.html

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!